BioSpace News Archive

argenx announced that it will host a conference call and audio webcast on Thursday, October 27, 2022 at 2:30 pm CET to discuss its third quarter 2022 financial results and provide a business update.

Innate Pharma SA released its 2023 financial calendar.

AlzeCure Pharma announced that an abstract with new preclinical Alzstatin data has been accepted for presentation at the annual Alzheimer conference CTAD, Clinical Trials in Alzheimer’s Disease, which this year is being held in San Francisco on November 29 - December 2.

Harbour BioMed announced that, it has successfully completed the dosing of first patient in the global phase I trial of B7H4x4-1BB bispecific antibody HBM7008 in the United States.

Vifor Pharma AG announced that by decision dated October 19, 2022, SIX Exchange Regulation AG has approved an extension of the various exemptions from certain disclosure and publicity obligations granted by SER to Vifor Pharma AG previously.

Alfasigma S.p.A. has completed the acquisition of SOFAR S.p.A., thus officially beginning the integrating process of the two companies.

According to the instructions for the Nomination Committee of Immunovia AB that were adopted at the Annual General Meeting on April 7, 2022, the Nomination Committee shall consist of four members.

BGI Australia’s lab has achieved accreditation from the National Association of Testing Authorities to perform clinical Whole Exome Sequencing in Australia, paving the way for the global life sciences company to provide clinical sequencing services for identifying possible disease-causing genetic changes.

AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, provided a business update and the outcome from its pre-planned 400-patient interim futility analysis for the pivotal phase 3 REVIVAL study, which has been stopped for futility based on the study’s primary endpoint.

Spago Nanomedical In accordance with a resolution at Spago Nanomedical AB’s Annual General Meeting on May 18, 2022, a Nomination Committee for the 2023 Annual General Meeting has been appointed.